Prime Medicine — November 2026 Earnings Summary

Prime Medicine is advancing its Prime Editing platform, a gene editing technology that corrects genetic mutations without causing double-strand breaks, with a focus on liver diseases including Wilson disease and Alpha-1 Antitrypsin Deficiency. The company has initiated clinical trials for PM577a targeting the H1069Q mutation in Wilson disease and cleared an IND for PM647 to treat Alpha-1 Antitrypsin Deficiency, with initial clinical data anticipated in 2027. Additionally, Prime Medicine is progressing PM359 for Chronic Granulomatous Disease toward a Biologics License Application submission in the first half of 2027 following successful ex vivo clinical results. The company has also established strategic collaborations, including a partnership with Bristol Myers Squibb for ex vivo CAR-T products and funding from the Cystic Fibrosis Foundation to develop therapies for Cystic Fibrosis.